Cellectar Biosciences Granted Orphan Drug Designation for CLR 131 to Treat Neuroblastoma Mar 19, 2018
Cellectar Biosciences to Host 2017 Financial Results and Business Update Conference Call on March 22, 2018 Mar 19, 2018
Cellectar Announces Late-Breaking Poster Presentations at AACR 2018 Featuring PDCs and CLR 131 Mar 15, 2018
Phase 1 Clinical Data Demonstrating CLR 124 Uptake in Brain Tumors Accepted for Oral Presentation at the 12th World Congress of the World Federation of Nuclear Medicine and Biology Mar 6, 2018
Cellectar Receives USPTO Notice of Allowance for Patent Covering Use of CLR 131 in Multiple Myeloma Feb 7, 2018
Cellectar Initiates DLBCL Cohort in Phase 2 Trial of CLR 131 in Refractory B-Cell Hematologic Cancers Jan 29, 2018
Cellectar Biosciences to Participate at Noble Capital Markets’ Fourteenth Annual Investor Conference Jan 22, 2018